Global Macro - The nomination of Kevin Warsh reflects a rebalancing of monetary policy under the constraints of the Trump 2.0 policy framework, aiming to enhance the alignment of monetary policy with growth and financing cost objectives [2] - Warsh's selection is seen as an optimal compromise, meeting Trump's criteria of being communicative, favoring low interest rates, and avoiding an immediate "independence crisis" narrative [2] - The significance of Warsh's nomination lies not in an immediate change in interest rates but in altering market expectations regarding the Federal Reserve's "toolbox weight" and "intervention boundaries," potentially triggering repricing of term premiums and volatility [2] Asset Implications - The interest rate curve is likely to steepen, with the Federal Reserve expected to tolerate higher long-term rates and risk asset volatility, leading to a scenario where short-term rates decrease while long-term rates remain stable or even rise [3] - The dollar may strengthen in the medium term, provided the narrative of independence is not compromised, despite potential interest rate cuts [3] - A systemic elevation in volatility is anticipated as the Federal Reserve gradually withdraws from micro-management, allowing asset prices to be determined more by fundamentals rather than liquidity illusions [3] Company Focus: NIO Inc. - NIO reported a positive earnings surprise for Q4 2025, with adjusted operating profit expected to reach between 700 million to 1.2 billion yuan, marking the first quarter of positive operating profit for the company [6] - This turning point is attributed to increased deliveries, a higher proportion of premium products, and cost reduction efforts, validating the operational leverage of its business model [6] - Looking ahead to 2026, while the first half may experience fluctuations in profit due to seasonal and cost pressures, the launch of new large SUV models in the second half is expected to boost gross margins, making the new vehicle cycle a key catalyst for valuation reassessment [6]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [3] Core Insights - The commercialization of ADC (Antibody-Drug Conjugates) is accelerating, with 20 ADC drugs approved globally, and 6 of them have been in the "billion-dollar club" for two consecutive years [30][31] - The report highlights the increasing competition in the ADC sector, with approximately 60 ADC drugs currently in clinical phase 3 and application stages [30] - Domestic innovative pharmaceutical companies are adopting various strategies for ADC capacity layout, with companies like Rongchang Biopharma transitioning from outsourcing to in-house production, while others like Kelong Biotechnology are building their own production bases [31][32] Summary by Sections Market Review - The pharmaceutical index rose by 0.14% this week, outperforming the CSI 300 index by 1.47 percentage points, ranking 15th in industry performance [10] - Year-to-date, the pharmaceutical index has increased by 3.28%, also outperforming the CSI 300 index by 2.99 percentage points, ranking 23rd [10] Individual Stock Performance - In the A-share market, 255 out of 479 pharmaceutical stocks rose, with the top five performers being Guangshengtang (+29.83%), Haixiang Pharmaceutical (+18.64%), and Meidixi (+18.04%) [20] - In the Hong Kong market, 38 out of 116 pharmaceutical stocks rose, with the top performers including Yiteng Jiahe (+14%) and Kedi-B (+9.96%) [24] Industry News and Policies - The newly revised "Regulations on the Implementation of the Drug Administration Law" supports segmented contract manufacturing and commercial-scale drug sales, providing a foundation for ADC commercialization cooperation [32] - Notable industry developments include Novartis's application for Ianalumab in China and Johnson & Johnson's approval of Daratumumab injection for multiple myeloma treatment [27][28] Weekly Insights - The ADC commercialization battle has begun, with a significant increase in demand for ADC production capacity, leading to a supply-demand imbalance [30] - Major CXO companies are expanding ADC production capacity, with companies like WuXi AppTec acquiring East Yao Pharmaceutical to meet rising orders [31]

研究报告 Research Report 9 Feb 2026 香港医疗 Hong Kong Health Care 医药行业周报（2026.02.02-2026.02.06）：市场情绪回暖；看好基本面表现强劲的创新药产业链龙头 Healthcare Weekly (2026.02.02-2026.02.06): Market Sentiment Warms; Bullish on Leaders in Innovative Drug Chain with Strong Fundamentals [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | 评级 | | 百济神州 | Outperform 华润医药 | | Outperform | | 京东健康 | Outperform 国药控股 | | Neutral | | 药明生物 | Outperform 映恩生物 | | Outperform | | 信达生物 | Outperform 金斯瑞生物科 ...

Macro Commentary - The report indicates a slowdown in China's economic growth in Q1, but improvements in deflation are noted, with policymakers signaling a focus on stabilizing real estate, promoting consumption, and countering "involution" [2] - The US economy is expected to rebound, with rental inflation declining, offsetting a rise in commodity inflation, leading to a stable dollar liquidity environment [2] - The report anticipates only one interest rate cut by the Federal Reserve in June this year, with a potential for a spring rebound in the stock market [2] Internet Sector - In January, high beta stocks benefitting from event-driven catalysts significantly outperformed the industry, aided by improved market risk appetite and liquidity [2] - Major Chinese internet companies are increasing market spending on AI applications targeting end-users, with 2026 identified as a critical year for capturing user engagement in the AI era [2] Stock Market Performance - The Hang Seng Index closed at 26,560, down 1.21% for the day but up 3.63% year-to-date, while the US markets showed a rebound with the Dow Jones up 2.47% [2] - The report highlights the performance of various indices, with the Hang Seng Financial Index down 1.89% and the Hang Seng Property Index up 17.49% year-to-date [3] Investment Strategy - A "barbell" investment strategy is recommended, focusing on companies with certain profit growth and those benefiting from AI [5] - Specific stocks to watch include Tencent, Alibaba, and Kuaishou for their AI-driven growth potential, and NetEase and Trip.com for their stable earnings visibility [5] Software and IT Services - The report expresses optimism for the software sector, expecting revenue growth to support valuations, while cautioning about the competitive pressures from AI model vendors [6] - Recommended stocks include Palo Alto Networks in the US and Kingdee in China, which are expected to benefit from AI-related revenue growth [6] Semiconductor Industry - The semiconductor sector is viewed positively, driven by AI demand, with structural shortages in memory products like HBM and server DRAM [7] - Recommended stocks include Zhongji Xuchuang and Northern Huachuang, which are expected to benefit from the ongoing demand for computing power [7] Technology Sector - The report anticipates a continued high demand for AI computing infrastructure and innovations in consumer electronics, with specific recommendations for companies like Luxshare Precision and BYD Electronics [8] Consumer Sector - The Hang Seng Consumer Index has risen 8% year-to-date, driven by high elasticity in discretionary consumption sectors [9] - The report highlights the potential for increased consumer spending during the Spring Festival, supported by government policies aimed at boosting consumption [10] Automotive Sector - January saw a slowdown in automotive sales, particularly in the new energy vehicle segment, but a recovery is expected post-Spring Festival [11] - Recommended stocks include Geely for its expanding new energy vehicle matrix and Xpeng for its potential to turn profitable [11] Pharmaceutical Sector - The report emphasizes the long-term trend of innovative drugs going global, with a focus on clinical progress and data validation for drugs already in international markets [12] - Recommended stocks include Innovent Biologics and CanSino Biologics, which are expected to benefit from the ongoing trend of drug commercialization [12] Capital Goods Sector - The report notes a positive outlook for the capital goods sector, particularly in construction machinery, driven by rising metal prices and increased mining capital expenditures [21] - Recommended stocks include SANY Heavy Industry and Zoomlion, which are expected to benefit from the ongoing demand for construction equipment [21] Real Estate and Property Management - The real estate sector is optimistic due to favorable policies, with the Hang Seng Property Index rising 15% year-to-date [19] - Recommended stocks include China Jinmao and Greentown China, which have shown significant price increases [19]

Group 1 - The Hong Kong stock market showed a strong opening on February 9, with the Hang Seng Index rising by 1.59%, the State-owned Enterprises Index increasing by 1.54%, and the Technology Index up by 1.9% [1] - The Hang Seng Biotechnology Index, focusing on innovative drugs, performed robustly, with the largest ETF tracking this index (159892) rising nearly 2% [1] - The innovative drug sector is expected to enter a profit realization acceleration phase by 2025, with companies like Innovent Biologics and Rongchang Biopharmaceuticals turning losses into profits, while companies like 3SBio are significantly increasing their performance [1] Group 2 - The strong performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core product volume growth supported by medical insurance becoming the foundation for performance growth [1] - External collaborations, such as business development (BD) partnerships, are becoming important drivers for enhancing performance in the innovative drug sector [1] - The Hang Seng Medical ETF (159892) focuses on innovative drugs, CXO, and related industries, benefiting from the advantages of the Hong Kong Stock Exchange's 18A system, covering numerous innovative targets like BeiGene and Innovent Biologics, and is expected to continue its valuation recovery trend under catalysts like overseas expansion of innovative drugs and commercial insurance directories [1]

Core Viewpoint - The Hong Kong stock market for innovative drugs is experiencing significant growth, with the Hong Kong Stock Connect Innovative Drug ETF (159570) rising nearly 2% and achieving a trading volume exceeding 750 million yuan, indicating renewed investor interest [1][3]. Group 1: Company Developments - Innovent Biologics announced a strategic partnership with Eli Lilly to advance global R&D in oncology and immunology, receiving an upfront payment of $350 million and potential milestone payments totaling up to $8.5 billion [3]. - The stock performance of key companies within the ETF is positive, with Innovent Biologics up over 4%, BeiGene and China National Pharmaceutical Group up over 3%, and CSPC Pharmaceutical Group and Hansoh Pharmaceutical up over 1% [3][4]. Group 2: Industry Trends - The Chinese innovative drug sector is transitioning from "scale accumulation" to "value release," with a projected increase in License-out transactions from $2.562 billion in 2017 to $140.274 billion by 2025, indicating a significant leap in global recognition [5]. - By 2025, over 70% of companies in the innovative drug sector are expected to achieve revenue growth, with companies like BeiGene reporting revenues exceeding 36 billion yuan, showcasing strong commercialization capabilities [6]. - The innovative drug sector is entering a phase of profitability, with companies like Innovent Biologics and Rongchang Biologics achieving breakeven, while others like Elysium and Rongchang Biologics maintain robust growth [9][11]. Group 3: Investment Opportunities - The innovative drug sector is expected to see a surge in clinical data releases in 2026, with major academic conferences likely to provide further validation for domestic innovative drugs [8]. - Investment strategies should focus on core areas such as small nucleic acids, bispecific antibodies, and ADCs, while also capitalizing on performance forecast windows to identify high-potential stocks [8][12].

2026年开年以来，国产创新药BD出海延续火热态势，此前石药-阿斯利康（185亿美元）、荣昌-艾伯维 （56亿美元）等重磅合作充分印证国产创新药国际竞争力提升，信达生物本次88.5亿美元大动作为创新 药出海再添一把火！ | 转让方 | 受让方 | 2026年以来中国创新药出海授权交易一览(部分 最高里程碑付款 | 首付款 | | --- | --- | --- | --- | | 石药集团 | 阿斯利康 | 173亿美元 | 12亿美元 | | 荣昌生物 | 艾伯维 | 49.5亿美元 | 6.5亿美元 | | 泽璟制药 | 艾伯维 | 11.35亿美元 | 1亿美元 | | 灰龍ણ | AirNexis | 9.55亿美元 | 1.08亿美元 | | 先声药业 | 勃林格殷格翰 | 10.16亿欧元 | 4200万欧元 | | 宜联生物 | 器联 | 5.7亿美元 | 未单独披露 | | 数据截至2026年1月30日。 | | | | 值得一提的是，港股通创新药板块当前处于阶段低位，港股通创新药ETF（520880）场内价格于上周创 下上市以来新低。低位吸纳创新药便宜筹码，认准港股通创新药ETF（52088 ...

Investment Rating - The report indicates a positive outlook for the pharmaceutical sector, particularly for innovative drugs and companies expected to reach profitability in 2025 [1][9][15]. Core Insights - The innovative drug sector is anticipated to see significant growth due to the commercialization of core products and contributions from business development (BD) revenues, with companies like BeiGene, Innovent Biologics, and others expected to achieve profitability [1][9]. - The Pharma sub-sector is projected to experience a revenue growth rate of 15-20% in 2025, with notable companies such as Hansoh Pharmaceutical and China Biologic Products leading this growth [2][10]. - The CXO sector is also expected to report strong performance, with companies like WuXi AppTec forecasting substantial revenue and profit increases [3][11]. - The medical services sector is currently valued at historical lows, with a projected revenue growth of 13% for Genscript Biotech, highlighting the importance of monitoring industry changes [4][12]. Summary by Sections Innovative Drugs - Companies expected to achieve profitability in 2025 include BeiGene, Innovent Biologics, and others, driven by increased commercialization and BD revenues [1][9]. Pharma - Revenue growth of 15-20% is expected for leading companies such as Hansoh Pharmaceutical and China Biologic Products, with a significant boost anticipated for 3SBio due to a major BD deal with Pfizer [2][10]. CXO - WuXi AppTec is projected to achieve approximately 454.56 billion RMB in revenue, reflecting a year-on-year growth of about 15.84%, with adjusted net profits expected to rise significantly [3][11]. Medical Services - Genscript Biotech is expected to see a revenue increase of 13% in 2025, emphasizing the need to focus on overseas business expansion and AI integration in traditional medicine [4][12].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The Chinese innovative pharmaceutical industry is entering a new phase of development characterized by dual breakthroughs in commercialization and internationalization, with significant growth in License-out transactions from $2.562 billion in 2017 to $140.274 billion in 2025 [5][15] - The industry is transitioning from a phase of pipeline expectations to one of performance realization, with over 70% of companies achieving positive revenue growth in 2025 [6][23] - The innovative drug sector has seen a strong performance in early 2026, with the pharmaceutical and biological sector rising by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [7][29] Summary by Sections Section 1: Breakthroughs in Commercialization and Internationalization - The period from 2017 to 2026 is crucial for the recognition of Chinese pharmaceutical companies in the global market, with a notable increase in License-out transactions [5][15] - In early 2026, significant deals were made, including a $12 billion upfront payment from CSPC to AstraZeneca, indicating the growing international competitiveness of Chinese innovative drugs [16][17] Section 2: Performance of the Pharmaceutical Sector - The pharmaceutical sector has shown robust growth, with companies like BeiGene reporting revenues exceeding 36 billion yuan, reflecting strong commercialization capabilities [6][23] - The overall industry is moving towards profitability, with companies like Innovent Biologics and Rongchang Biopharma achieving breakeven for the first time [6][23] Section 3: Market Trends and Subsector Performance - In the first week of February 2026, the Chinese pharmaceutical sector saw a 0.14% increase, with traditional Chinese medicine leading the gains at 2.56% [7][31] - The medical research outsourcing sector also performed well, increasing by 1.99%, while other subsectors like biological products and vaccines experienced declines [7][31][35]

Market Overview - A-shares experienced volatility on February 6, with the Shanghai Composite Index closing down 0.25% at 4065.58 points, and the ChiNext Index down 0.73% [1] - The overall market turnover decreased to 2.16 trillion yuan, marking a continuous six-day decline in trading volume [1] Sector Performance - The chemical and new energy sectors led the market, while the pharmaceutical sector showed relative resilience. Consumer goods experienced a pullback, and technology continued to be sluggish [1] - The chemical ETF (516020) saw a significant inflow of 199 billion yuan, with a daily gain of 2.37% after reaching a peak increase of 3.45% during the day [2][5][6][8] Chemical Sector Insights - The chemical sector is experiencing a strong upward cycle, driven by increased demand for lithium batteries and key chemical materials [9][10] - Major stocks in the chemical sector, such as Enjie Co., Ltd. and Zhejiang Longsheng, saw significant gains, with some stocks rising over 6% [6][9] Non-Ferrous Metals Sector - The non-ferrous metals sector demonstrated resilience, with the non-ferrous ETF (159876) reversing early losses to close slightly up by 0.18% despite fluctuations in international gold prices [3][11] - Over 100 billion yuan of main funds flowed into the non-ferrous metals sector, indicating strong investor interest [11] Hong Kong Market Dynamics - The Hong Kong market experienced a downward trend, with the Hang Seng Index and Hang Seng Tech Index both closing down over 1% [3] - Despite the overall decline, there was significant buying activity from southbound funds, with purchases reaching 133.7 billion HKD, 249.8 billion HKD, and 148.6 billion HKD over three days [4] Pharmaceutical Sector Developments - The Hong Kong pharmaceutical sector showed signs of recovery, with the innovative drug ETF (520880) rising by 2% during the day, driven by strong earnings forecasts from key companies [15][16] - Notable performers included Innovent Biologics, which projected a revenue increase of approximately 134% by 2025, and several other companies expecting significant profit growth [16][18] Investment Opportunities - Analysts suggest that the chemical sector remains a promising investment opportunity, particularly in leading companies and price recovery products [10][22] - For investors looking to capitalize on the pharmaceutical sector, the innovative drug ETF (520880) and the medical ETF (159137) are recommended for their strong growth potential and coverage of key industry players [21][22]